Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VVOS Vivos Therapeutics

Trading 11-05 09:42:08 EST

2.66

-0.03

-1.11%

High2.71	Low2.66	Vol1.37K
Open2.71	D1 Closing2.69	Amplitude1.86%
Mkt Cap12.68M	Tradable Cap12.14M	Total Shares4.77M
T/O3.65K	T/O Rate0.03%	Tradable Shares4.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VVOS","market":"US","secType":"STK","nameCN":"Vivos Therapeutics","latestPrice":2.6601,"timestamp":1730817619228,"preClose":2.69,"halted":0,"volume":1366,"delay":0,"floatShares":4563400,"shares":4765300,"eps":-5.907127,"marketStatus":"Trading","change":-0.0299,"latestTime":"11-05 09:42:08 EST","open":2.71,"high":2.71,"low":2.6601,"amount":3646.4121476,"amplitude":0.01855,"askPrice":2.7,"askSize":2,"bidPrice":2.67,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-5.907127,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1730840400000},"marketStatusCode":2,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":2.69,"preHourTrading":{"tag":"盘前","latestPrice":2.69,"preClose":2.69,"latestTime":"09:28 EST","volume":77,"amount":204.894998,"timestamp":1730816936299},"postHourTrading":{"tag":"盘后","latestPrice":2.69,"preClose":2.69,"latestTime":"19:59 EST","volume":45,"amount":119.88,"timestamp":1730768385852},"volumeRatio":0.439159,"impliedVol":2.6041,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/VVOS/wiki","defaultTab":"wiki","newsList":[{"id":"2473842344","title":"Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association","url":"https://stock-news.laohu8.com/highlight/detail?id=2473842344","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473842344?lang=en_us&edition=fundamental","pubTime":"2024-10-08 19:30","pubTimestamp":1728387000,"startTime":"0","endTime":"0","summary":"New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and ChildrenLITTLETON, Colo., Oct.  08, 2024  (GLOBE NEWSWIRE) -- Vivos Th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/08/2959585/0/en/Vivos-Therapeutics-Granted-CPT-Coverage-and-Reimbursement-Codes-for-All-Vivos-CARE-Oral-Medical-Devices-From-American-Medical-Association.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","BK4196","BK4211","BK4107","VVOS","CARE","VIP","CPT","BK4585","BK4588","BK4215","AFG"],"gpt_icon":0},{"id":"2468650726","title":"Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2468650726","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468650726?lang=en_us&edition=fundamental","pubTime":"2024-09-20 00:39","pubTimestamp":1726763967,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/09/40943940/dow-jumps-over-500-points-factset-research-posts-upbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","PCOM","VVOS","HAO","SGN","PGNY","FDS","MBLY"],"gpt_icon":0},{"id":"2468250614","title":"Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2468250614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468250614?lang=en_us&edition=fundamental","pubTime":"2024-09-19 23:06","pubTimestamp":1726758360,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering.Shares were down 27% to $3.03 in recent trading after closing at $4.13 on Wednesday. The stock is down almost 76% this year.The offering is expected to close by Friday.The Colorado company said it expects to see about $4.3 million in proceeds from the offering before fees and expenses. It currently intends to use the net proceeds for working capital and general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2468763355","title":"Vivos Therapeutics Prices $4.3 Million Common Stock Offering; Shares Fall Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2468763355","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468763355?lang=en_us&edition=fundamental","pubTime":"2024-09-19 20:23","pubTimestamp":1726748583,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics  said Thursday is selling about 1.4 million common shares at $3.15 apiece in a registered direct offering for gross proceeds of roughly $4.3 million.Priced at-the-market under Nasdaq rules, the offering is expected to close around Friday, the company said.The company said it plans to use the net proceeds for working capital and general corporate purposes.Shares of Vivos Therapeutics slid 23% in premarket activity on Thursday.Price: 3.1800, Change: -0.95, Percent Change: -23.00","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2468575873","title":"Vivos Therapeutics announces $4.3M registered direct offering of common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2468575873","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468575873?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:53","pubTimestamp":1726746825,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics has entered into agreement for direct offering of an aggregate of 1.36M common shares at $3.15 per share for gross proceeds of ~$4.3M Closing date is September 20. The net proceeds will be used for the offering for working capital and general corporate purposes. VVOS  -21.5% premarket to  $3.24","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4151037-vivos-therapeutics-announces-43m-registered-direct-offering-of-common-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["TQQQ","PSQ","NQmain","MNQmain","QLD","BK4196","VVOS",".IXIC","SQQQ","QID"],"gpt_icon":0},{"id":"2468157818","title":"BRIEF-Vivos Therapeutics Prices $4.3 Mln Registered Direct Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2468157818","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468157818?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:38","pubTimestamp":1726745928,"startTime":"0","endTime":"0","summary":"Sept 19  - Vivos Therapeutics Inc   :   * VIVOS THERAPEUTICS ANNOUNCES PRICING OF $4.3 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES   * VIVOS THERAPEUTICS INC - TO ISSUE 1,363,812 SHARES AT $3.15 EACHSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","TQQQ","NQmain","PSQ","QLD","BK4196","QID","MNQmain","SQQQ","VVOS"],"gpt_icon":0},{"id":"2468743522","title":"Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2468743522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468743522?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:00","pubTimestamp":1726743602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240919:nTUA7KLSYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2468527580","title":"Vivos Therapeutics Inc - to Issue 1,363,812 Shares at $3.15 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2468527580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468527580?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:00","pubTimestamp":1726743602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240919:nTUA7KLSYL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2468527326","title":"Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2468527326","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468527326?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:00","pubTimestamp":1726743600,"startTime":"0","endTime":"0","summary":"LITTLETON, Colo., Sept.  19, 2024  (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc.(“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the developmen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/19/2948870/0/en/Vivos-Therapeutics-Announces-Pricing-of-4-3-Million-Registered-Direct-Offering-of-Common-Stock-Priced-At-The-Market-Under-Nasdaq-Rules.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","BK4585","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","BK4588","CARE","LU2095319765.USD","BK4196","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","IE00BGHQF748.EUR","VVOS","IE00B64PRP62.GBP","BK4211"],"gpt_icon":0},{"id":"2468553156","title":"Vivos surges on FDA nod for pediatric sleep apnea device","url":"https://stock-news.laohu8.com/highlight/detail?id=2468553156","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468553156?lang=en_us&edition=fundamental","pubTime":"2024-09-19 01:25","pubTimestamp":1726680342,"startTime":"0","endTime":"0","summary":"Shares of Vivos Therapeutics  climbed on Wednesday after MedTech announced the FDA's 510 clearance for its DNA appliance as a treatment for children with obstructive sleep apnea  and snoring. Accordingly, DNA, Vivos'  flagship oral medical device, will be available in the U.S. to reduce snoring and treat moderate to severe OSA in children aged 6 to 17. The company called the device a medical breakthrough, noting that surgical interventions tend to fail in children with OSA. Meanwhile, given their impact on growth, CPAP devices such as those manufactured by ResMed  and Philips  are not widely prescribed for the age group.  \"The FDA 510 clearance announced today is, to our knowledge, the first time any oral medical device has ever been approved to treat moderate to severe OSA in children,\" CEO Kirk Huntsman added.","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213293784/image_1213293784.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213293784/image_1213293784.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4150816-vivos-stock-surges-fda-nod-osa-device","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4196","BK4585","BK4548","LU2008162690.USD","BK4504","BK4082","LU2177674079.SGD","PHG","RMD","BK4567","BK4588","VVOS"],"gpt_icon":0},{"id":"2468580481","title":"BUZZ-Vivos Therapeutics rises on FDA approval for pediatric sleep apnea device","url":"https://stock-news.laohu8.com/highlight/detail?id=2468580481","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468580481?lang=en_us&edition=fundamental","pubTime":"2024-09-18 22:47","pubTimestamp":1726670826,"startTime":"0","endTime":"0","summary":"** Shares of medtech firm Vivos Therapeutics    rise 24.4% to five-month high of $3.48    ** Co says U.S. FDA has granted clearance for its sleep apnea device    ** The device is designed to reduce nighttime snoring and treat moderate to severe obstructive sleep apnea in children aged 6 to 17   ** Obstructive sleep apnea  is the most common sleep-related breathing disorder with symptoms including snoring and  daytime fatigue    ** The clearance was based on a study that showed the device reduced snoring by 58% in pediatric patients and also reduced other OSA symptoms such as fatigue and lack of attention   ** There were no safety concerns reported in the study - co    ** Including session moves, stock down 71.6% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2468582789","title":"Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children","url":"https://stock-news.laohu8.com/highlight/detail?id=2468582789","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468582789?lang=en_us&edition=fundamental","pubTime":"2024-09-18 22:05","pubTimestamp":1726668342,"startTime":"0","endTime":"0","summary":"On Wednesday, the FDA granted 510 clearance to Vivos Therapeutics, Inc.’s flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea  and snoring in children.Recent published studies report up to 10.1 million U.S. children  are estimated to suffer from pediatric OSA.Vivos’ DNA appliance is non-invasive, safe, comfortable, affordable, and highly effective. It is designed to reduce nighttime snoring and treat moderate to severe obstructive sleep apnea in children aged 6 to 17.The Vivos device is intended for those diagnosed with snoring and/or OSA requiring orthodontic treatment.Vivos believes this breakthrough regulatory clearance represents a huge opportunity to capture significant market share.Further, Vivos believes it can immediately leverage this FDA clearance by quickly integrating pediatric care into its new provider-based marketing and distribution model and scale revenue relatively quickly with minimal investment.In November, Vivos received ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3oawP5pTpJ2IQ6DgZWBAtA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/ddc73764de0faaeec8d8009f0e194ee8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3oawP5pTpJ2IQ6DgZWBAtA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/ddc73764de0faaeec8d8009f0e194ee8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vivos-therapeutics-says-poised-disrupt-140542467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VVOS","BK4196","DNA","BK4139","BK4109"],"gpt_icon":0},{"id":"2468584784","title":"Vivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2468584784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468584784?lang=en_us&edition=fundamental","pubTime":"2024-09-18 21:57","pubTimestamp":1726667820,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics shares rose on Wednesday after the company said its oral medical device for pediatric sleep apnea and snoring received 510 clearance from the Food and Drug Administration.Shares were up 24% to $3.47 in recent trading. However, shares are down more than 50% on a 52-week basis.The medical technology company, which makes devices to treat sleep disorders, said this is believed to be the first ever FDA clearance to treat moderate to severe obstructive sleep apnea and snoring in children.The 510 clearance allows medical devices to enter the U.S. market with no clinical trial requirement, as submitters must compare their device to other similar legally marketed devices and support their equivalence claims.The company said it can immediately leverage the clearance by quickly integrating pediatric care into its new marketing and distribution model, and also scale revenue with minimal investment.\"Vivos believes this breakthrough regulatory clearance represents a huge opportuni","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2468307134","title":"Vivos Therapeutics' Sleep Disorder Treatment Device Receives FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2468307134","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468307134?lang=en_us&edition=fundamental","pubTime":"2024-09-18 19:37","pubTimestamp":1726659458,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics  said Wednesday that it received the US Food and Drug Administration's 510 clearance for its oral medical device, which treats moderate to severe obstructive sleep apnea.The company said the noninvasive, safe, and effective device is part of its CARE line and intended for children diagnosed with obstructive sleep apnea or snoring who need orthodontic treatment.The approval was based on a multi-site, multi-nation study in pediatric patients.Price: 3.4000, Change: +0.60, Percent Change: +21.43","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2468045923","title":"Vivos Therapeutics Receives Groundbreaking FDA 510(K) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2468045923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468045923?lang=en_us&edition=fundamental","pubTime":"2024-09-18 19:00","pubTimestamp":1726657201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240918:nTUAZFPYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2468612304","title":"Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2468612304","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468612304?lang=en_us&edition=fundamental","pubTime":"2024-09-18 19:00","pubTimestamp":1726657200,"startTime":"0","endTime":"0","summary":"Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now approv","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/18/2948068/0/en/Vivos-Therapeutics-Receives-Groundbreaking-FDA-510-k-Clearance-to-Treat-Moderate-to-Severe-Pediatric-Sleep-Apnea-and-Snoring.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADHD","BK4097","CARE","BK4196","AHI","BK4211","VVOS","BK4167"],"gpt_icon":0},{"id":"2467473753","title":"Vivos Therapeutics Enhances Incentives and Executive Pay Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2467473753","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467473753?lang=en_us&edition=fundamental","pubTime":"2024-09-13 05:29","pubTimestamp":1726176553,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Vivos Therapeutics ( ($VVOS) ). Vivos Therapeutics, Inc. is set to incentivize its workforce and align their in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-enhances-incentives-and-executive-pay-structure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-enhances-incentives-and-executive-pay-structure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2466498127","title":"Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2466498127","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466498127?lang=en_us&edition=fundamental","pubTime":"2024-09-10 22:24","pubTimestamp":1725978267,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shareholders would be excited to see that the share price has had a great...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-vvos/vivos-therapeutics/news/vivos-therapeutics-incs-nasdaqvvos-shares-leap-41-yet-theyre","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","LU2210150020.SGD","BK4196","QID","NDAQ","NQmain","LU2210149790.SGD","PSQ","IE00B64PRP62.GBP","TQQQ","MNQmain",".IXIC","SQQQ","IE00BGHQF748.EUR","BK4585","VVOS","BK4112"],"gpt_icon":1},{"id":"2460607821","title":"Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2460607821","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460607821?lang=en_us&edition=fundamental","pubTime":"2024-08-20 17:46","pubTimestamp":1724147160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VVOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 20, 2024 05:46 ET (09:46 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS"],"gpt_icon":0},{"id":"2459477338","title":"Vivos Therapeutics GAAP EPS of -$0.60, revenue of $4.1M","url":"https://stock-news.laohu8.com/highlight/detail?id=2459477338","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459477338?lang=en_us&edition=fundamental","pubTime":"2024-08-16 00:08","pubTimestamp":1723738097,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics press release  (NASDAQ:VVOS): Q2  GAAP EPS of -$0.60.\nRevenue of $4.1M.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4140655-vivos-therapeutics-gaap-eps-of-0_60-revenue-of-4_1m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["VVOS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vivos.com","stockEarnings":[{"period":"1week","weight":-0.0724},{"period":"1month","weight":0.0717},{"period":"3month","weight":0.2454},{"period":"6month","weight":0.1326},{"period":"1year","weight":-0.2135},{"period":"ytd","weight":-0.7838}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.377066},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037873},{"month":3,"riseRate":0,"avgChangeRate":-0.230737},{"month":4,"riseRate":0.5,"avgChangeRate":-0.19387},{"month":5,"riseRate":0.5,"avgChangeRate":-0.029275},{"month":6,"riseRate":0.5,"avgChangeRate":-0.011445},{"month":7,"riseRate":0.25,"avgChangeRate":-0.222928},{"month":8,"riseRate":0.75,"avgChangeRate":0.213255},{"month":9,"riseRate":0,"avgChangeRate":-0.24401},{"month":10,"riseRate":0.25,"avgChangeRate":-0.089926},{"month":11,"riseRate":0.5,"avgChangeRate":1.524196},{"month":12,"riseRate":0,"avgChangeRate":-0.268631}],"exchange":"NASDAQ","name":"Vivos Therapeutics","nameEN":"Vivos Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vivos Therapeutics,VVOS,Vivos Therapeutics股票,Vivos Therapeutics股票老虎,Vivos Therapeutics股票老虎国际,Vivos Therapeutics行情,Vivos Therapeutics股票行情,Vivos Therapeutics股价,Vivos Therapeutics股市,Vivos Therapeutics股票价格,Vivos Therapeutics股票交易,Vivos Therapeutics股票购买,Vivos Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction